Home › Breast Cancer › Connecticut
Breast Cancer clinical trials in Connecticut
50 studies for Breast Cancer are looking for participants at sites in Connecticut.
Cities in Connecticut
- East Norwalk38 studies
- New Haven38 studies
- Bridgeport22 studies
- Hartford10 studies
- Stamford9 studies
- Waterbury6 studies
- New London5 studies
- Norwalk5 studies
- North Stamford4 studies
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Yale University - Yale University School of Medicine, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07360314An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07222267A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Eastern CT Hematology and Oncology Associates, Norwich
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT07541079Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT04557449A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Yale University School of Medicine, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Hartford Healthcare Institute, Hartford
- Yale Cancer Center, New Haven
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- UConn Health, Farmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336E-Mindfulness Approaches for Living After Breast Cancer
- Stamford Hospital/Bennett Cancer Center, Stamford
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Hartford HealthCare - Avon, Avon
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Danbury Hospital, Danbury
- and 19 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Yale University School Of Medicine, New Haven
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT07524855A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Smilow Cancer Hospital Care Center - Derby, Derby
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield
- Smilow Cancer Hospital at Glastonbury, Glastonbury
- and 10 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 2, 2026 · NCT06377852A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478The Cancer of the Pancreas Screening-5 CAPS5)Study
- Yale University, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT02000089A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Smilow Cancer Hospital - Derby, Derby
- Smilow Cancer Hospital - Fairfield, Fairfield
- Smilow Cancer Hospital - Glastonbury, Glastonbury
- and 11 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Stamford Hospital ( Site 0049), Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06312176Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Yale University, Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
- Yale University, New Haven
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Oct 9, 2026 · NCT06749210A Study of PHST001 in Advanced Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Yale University School of Medicine - Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07701941Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- Norwalk Hospital, Norwalk
RecruitingPhase 2
Ages 45 and older · Women · Updated Sep 21, 2026 · NCT04084730Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Yale Cancer Center Clinical Trials Office, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Smilow Cancer Hospital at Yale New Haven, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Yale University Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06533826Optimizing Surgical Decisions in Young Adults With Breast Cancer
- Yale Cancer Center, New Haven
Recruiting
Ages 18 to 44 · Women · Updated Aug 19, 2026 · NCT06275126ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Smilow Cancer Hospital Care center at Derby, Derby
- Smilow Cancer Hospital Care center at Fairfield, Fairfield
- Smilow Cancer Hospital Care center at Glastonbury, Glastonbury
- and 11 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04893109Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Norwalk Hospital, Norwalk
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Pre-Operative Window of ET to Inform RT Decisions (POWER II)
- Yale University, New Haven
RecruitingPhase 3
Ages 65 and older · Women · Updated Jun 30, 2026 · NCT06507618Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Yale Cancer Center, New Haven
RecruitingObservational study
Ages 18 to 80 · Women · Updated May 22, 2026 · NCT06551220From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.